FN1 and pulmonary fibrosis: FN1 inhibitors, including monoclonal antibodies and small molecules, modulate cell behavior, reduce inflammation, and may reverse fibrosis, with therapeutic applications in fibrotic diseases such as liver cirrhosis, pulmonary fibrosis, and kidney fibrosis (Spada et al., 2021).